DE60207442D1 - VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION - Google Patents
VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTIONInfo
- Publication number
- DE60207442D1 DE60207442D1 DE60207442T DE60207442T DE60207442D1 DE 60207442 D1 DE60207442 D1 DE 60207442D1 DE 60207442 T DE60207442 T DE 60207442T DE 60207442 T DE60207442 T DE 60207442T DE 60207442 D1 DE60207442 D1 DE 60207442D1
- Authority
- DE
- Germany
- Prior art keywords
- carnitine
- propionyl
- dysfunction
- treating
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- WGAOZGUUHIBABN-UHFFFAOYSA-N 1-aminopentan-1-ol Chemical compound CCCCC(N)O WGAOZGUUHIBABN-UHFFFAOYSA-N 0.000 abstract 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 229960004046 apomorphine Drugs 0.000 abstract 1
- -1 apomorphine prostaglandin Chemical class 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 229960001789 papaverine Drugs 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM20010708 | 2001-12-04 | ||
| IT2001RM000708A ITRM20010708A1 (it) | 2001-12-04 | 2001-12-04 | Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. |
| PCT/IT2002/000758 WO2003047563A1 (en) | 2001-12-04 | 2002-12-04 | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60207442D1 true DE60207442D1 (de) | 2005-12-22 |
| DE60207442T2 DE60207442T2 (de) | 2006-07-27 |
Family
ID=11455907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60207442T Expired - Lifetime DE60207442T2 (de) | 2001-12-04 | 2002-12-04 | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20050080018A1 (de) |
| EP (1) | EP1450782B9 (de) |
| JP (1) | JP4370169B2 (de) |
| KR (1) | KR100907938B1 (de) |
| AT (1) | ATE309800T1 (de) |
| AU (1) | AU2002365847A1 (de) |
| CA (1) | CA2465471C (de) |
| DE (1) | DE60207442T2 (de) |
| DK (1) | DK1450782T3 (de) |
| ES (1) | ES2250749T3 (de) |
| HU (1) | HU229214B1 (de) |
| IT (1) | ITRM20010708A1 (de) |
| MX (1) | MXPA04005269A (de) |
| PL (1) | PL211211B1 (de) |
| SI (1) | SI1450782T1 (de) |
| WO (1) | WO2003047563A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040561A1 (it) * | 2004-11-11 | 2005-02-11 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile. |
| IT1397867B1 (it) * | 2010-02-03 | 2013-02-04 | Brotzu | Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
| KR102309654B1 (ko) | 2013-04-18 | 2021-10-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| WO2016174155A1 (en) * | 2015-04-30 | 2016-11-03 | Boehringer Ingelheim International Gmbh | Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
| ATE187329T1 (de) * | 1996-03-04 | 1999-12-15 | Sigma Tau Ind Farmaceuti | Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans |
| IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| US6133281A (en) * | 1996-10-24 | 2000-10-17 | Harbor-Ucla Research And Education Institute | NMDA receptor blockers in the therapy of urogenital disease |
| IT1293539B1 (it) * | 1997-07-16 | 1999-03-01 | Sigma Tau Ind Farmaceuti | Composizione nutritiva per soggetti in stato di debilitazione causato da stress |
| US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
| US6241471B1 (en) * | 1999-08-26 | 2001-06-05 | General Electric Co. | Turbine bucket tip shroud reinforcement |
| IT1306722B1 (it) * | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
-
2001
- 2001-12-04 IT IT2001RM000708A patent/ITRM20010708A1/it unknown
-
2002
- 2002-12-04 US US10/497,498 patent/US20050080018A1/en not_active Abandoned
- 2002-12-04 SI SI200230234T patent/SI1450782T1/sl unknown
- 2002-12-04 EP EP02804338A patent/EP1450782B9/de not_active Expired - Lifetime
- 2002-12-04 JP JP2003548819A patent/JP4370169B2/ja not_active Expired - Fee Related
- 2002-12-04 DK DK02804338T patent/DK1450782T3/da active
- 2002-12-04 DE DE60207442T patent/DE60207442T2/de not_active Expired - Lifetime
- 2002-12-04 ES ES02804338T patent/ES2250749T3/es not_active Expired - Lifetime
- 2002-12-04 KR KR1020047007882A patent/KR100907938B1/ko active IP Right Grant
- 2002-12-04 CA CA2465471A patent/CA2465471C/en not_active Expired - Fee Related
- 2002-12-04 MX MXPA04005269A patent/MXPA04005269A/es active IP Right Grant
- 2002-12-04 WO PCT/IT2002/000758 patent/WO2003047563A1/en active IP Right Grant
- 2002-12-04 HU HU0402062A patent/HU229214B1/hu not_active IP Right Cessation
- 2002-12-04 PL PL371131A patent/PL211211B1/pl unknown
- 2002-12-04 AT AT02804338T patent/ATE309800T1/de active
- 2002-12-04 AU AU2002365847A patent/AU2002365847A1/en not_active Abandoned
-
2007
- 2007-01-05 US US11/649,796 patent/US20070117762A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,749 patent/US8343979B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050044594A (ko) | 2005-05-12 |
| WO2003047563A1 (en) | 2003-06-12 |
| ITRM20010708A0 (it) | 2001-12-04 |
| EP1450782B1 (de) | 2005-11-16 |
| US20050080018A1 (en) | 2005-04-14 |
| US8343979B2 (en) | 2013-01-01 |
| DE60207442T2 (de) | 2006-07-27 |
| MXPA04005269A (es) | 2004-10-11 |
| US20070117762A1 (en) | 2007-05-24 |
| AU2002365847A1 (en) | 2003-06-17 |
| PL211211B1 (pl) | 2012-04-30 |
| JP2005511655A (ja) | 2005-04-28 |
| DK1450782T3 (da) | 2006-02-20 |
| ITRM20010708A1 (it) | 2003-06-04 |
| US20120041005A1 (en) | 2012-02-16 |
| JP4370169B2 (ja) | 2009-11-25 |
| PL371131A1 (en) | 2005-06-13 |
| EP1450782B9 (de) | 2006-05-17 |
| CA2465471C (en) | 2010-10-19 |
| HUP0402062A3 (en) | 2012-09-28 |
| ES2250749T3 (es) | 2006-04-16 |
| HU229214B1 (hu) | 2013-09-30 |
| HUP0402062A2 (hu) | 2005-02-28 |
| KR100907938B1 (ko) | 2009-07-16 |
| EP1450782A1 (de) | 2004-09-01 |
| CA2465471A1 (en) | 2003-06-12 |
| ATE309800T1 (de) | 2005-12-15 |
| SI1450782T1 (sl) | 2006-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1796660T (pt) | Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta | |
| BR0212924A (pt) | Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma | |
| TW200724033A (en) | Anthranilamide arthropodicide treatment | |
| ATE247117T1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
| ATE430573T1 (de) | Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen | |
| ATE497809T1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
| ATE518529T1 (de) | Wundauflage | |
| ATE464895T1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen | |
| DOP2002000447A (es) | 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas | |
| DE60328517D1 (de) | Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung | |
| DE60216495D1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| CL2007002389A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de obesidad, hirsutismo, hipertricosis y verrugas viricas. | |
| DE60026146D1 (de) | Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction | |
| DE69904173D1 (de) | Nervenschützende zusammensetzung zur prophylaxe und behandlung von nervös- und verhaltungsänderungen durch angstartigen zuständen oder depressionen, die acetyl-l-carnitin und hypericin enthalt | |
| UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
| DE60207442D1 (de) | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION | |
| ATE300295T1 (de) | Verwendung von baclofen zur behandlung von alkoholismus | |
| PT1030667E (pt) | Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono | |
| DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
| FI20000635A0 (fi) | COMT-inhibiittoreiden käyttö analgeettina | |
| DE69931487D1 (de) | Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation | |
| DE60313886D1 (de) | Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas | |
| UY27031A1 (es) | Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
| DE60336417D1 (de) | Flüssige zusammensetzungen mit 3,7-diazabicycloä3,3,1ü nonanen zur behandlung von anti-arrhythmischen ereignissen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |